Surgical Oncology
Volume 15, Issue 1 , Pages 13-24 , July 2006

The treatment of melanoma with an emphasis on immunotherapeutic strategies

References 

  1. Kadison AS, Morton DL. Immunotherapy of malignant melanoma. Surgical Clinics of North America. 2003;83(2):343–370
  2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA—A Cancer Journal for Clinicians. 2004;54(1):8–29
  3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA—A Cancer Journal for Clinicians. 2005;55(1):10–30
  4. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. Journal of American Academy of Dermatology. 1996;34(5 Pt 1):839–847
  5. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA—A Cancer Journal for Clinicians. 2000;50(4):215–236(quiz 237–40)
  6. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Annals of Surgery. 1970;172(5):902–908
  7. Greene FL. TNM: our language of cancer. CA—A Cancer Journal for Clinicians. 2004;54(3):129–130
  8. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, et al. An evidence-based staging system for cutaneous melanoma. CA—A Cancer Journal for Clinicians. 2004;54(3):131–149(quiz 182–4)
  9. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Annals of Surgery. 1991;214(4):491–499(discussion 499–501)
  10. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970;68(1):158–163discussion 163–4
  11. Morton DL, Malmgren RA, Holmes EC, Ketcham AS. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968;64(1):233–240
  12. Mukherji B, Wilhelm SA, Guha A, Ergin MT. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. Journal of Immunology. 1986;136(5):1888–1892
  13. Aitken DR, James AG, Carey LC. Local cutaneous recurrence after conservative excision of malignant melanoma. Archives of Surgery. 1984;119(6):643–646
  14. Breslow A, Macht SD. Optimal size of resection margin for thin cutaneous melanoma. Surgery Gynecology and Obstetrics. 1977;145(5):691–692
  15. Taylor BA, Hughes LE. A policy of selective excision for primary cutaneous malignant melanoma. European Journal of Surgical Oncology. 1985;11(1):7–13
  16. Elder DE, Guerry Dt, Heiberger RM, LaRossa D, Goldman LI, Clark WH, et al. Optimal resection margin for cutaneous malignant melanoma. Plastic and Reconstructive Surgery. 1983;71(1):66–72
  17. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Archives of Surgery. 1991;126(4):438–441
  18. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4mm). Results of a multi-institutional randomized surgical trial. Annals of Surgery. 1993;218(3):262–267(discussion 267–9)
  19. Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S, et al. Resection margins of 2 versus 5cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0mm: randomized study by the Swedish Melanoma Study Group. Cancer. 1996;77(9):1809–1814
  20. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, et al. Surgical margins in cutaneous melanoma (2cm versus 5cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97(8):1941–1946
  21. Lens MB, Dawes M, Goodacre T, Bishop JA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow vs. wide excision. Archives of Surgery. 2002;137(10):1101–1105
  22. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. Journal of Clinical Oncology. 2001;19(16):3635–3648
  23. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of Clinical Oncology. 2001;19(16):3622–3634
  24. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Archives of Surgery. 2004;139(9):961–966(discussion 966–7)
  25. Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Current Opinion in Oncology. 2004;16(2):155–160
  26. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. Cancer. 2006;
  27. Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH. Inhibition of interleukin 2 production by factors released from tumor cells. Journal of Immunology. 1983;131(6):2837–2842
  28. Hsueh EC, Gupta RK, Yee R, Leopoldo ZC, Qi K, Morton DL. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?. Annals of Surgical Oncology. 2000;7(3):232–238
  29. Allen PJ, Coit DG. The surgical management of metastatic melanoma. Annals of Surgical Oncology. 2002;9(8):762–770
  30. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. Journal of Neurosurgery. 2000;93(1):9–18
  31. Ricaniadis N, Konstadoulakis MM, Walsh D, Karakousis CP. Gastrointestinal metastases from malignant melanoma. Surgical Oncology. 1995;4(2):105–110
  32. Panagiotou I, Brountzos EN, Bafaloukos D, Stoupis C, Brestas P, Kelekis DA. Malignant melanoma metastatic to the gastrointestinal tract. Melanoma Research. 2002;12(2):169–173
  33. Rose DM, Essner R, Hughes TM, Tang PC, Bilchik A, Wanek LA, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Archives of Surgery. 2001;136(8):950–955
  34. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Annals of Surgery. 1999;230(4):453–463(discussion 463–5)
  35. Pawlik TM, Ross MI, Gershenwald JE. Lymphatic mapping in the molecular era. Annals of Surgical Oncology. 2004;11(4):362–374
  36. Ross MI, Reintgen D, Balch CM. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Seminars in Surgical Oncology. 1993;9(3):219–223
  37. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. Journal of Clinical Oncology. 1999;17(3):976–983
  38. Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, et al. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. Journal of Clinical Oncology. 2005;23(25):6054–6062
  39. Morton DL, Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Annals of Surgery. 2003;238(4):538–549(discussion 549–50)
  40. Thomas JM, Clark MA. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. European Journal of Surgical Oncology. 2004;30(6):686–691
  41. Estourgie SH, Nieweg OE, Kroon BB. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. British Journal of Surgery. 2004;91(10):1370–1371
  42. Day CL, Harrist TJ, Gorstein F, Sober AJ, Lew RA, Friedman RJ, et al. Malignant melanoma. Prognostic significance of “microscopic satellites” in the reticular dermis and subcutaneous fat. Annals of Surgery. 1981;194(1):108–112
  43. Leon P, Daly JM, Synnestvedt M, Schultz DJ, Elder DE, Clark WH. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Archives of Surgery. 1991;126(12):1461–1468
  44. Wong JH, Cagle LA, Kopald KH, Swisher SG, Morton DL. Natural history and selective management of in transit melanoma. Journal of Surgical Oncology. 1990;44(3):146–150
  45. Cascinelli N, Bufalino R, Marolda R, Belli F, Nava M, Galluzzo D, et al. Regional non-nodal metastases of cutaneous melanoma. European Journal of Surgical Oncology. 1986;12(2):175–180
  46. Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. Journal of Clinical Oncology. 2005;23(21):4588–4590
  47. Kretschmer L, Beckmann I, Thoms KM, Haenssle H, Bertsch HP, Neumann C. Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas. European Journal of Cancer. 2005;41(4):531–538
  48. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum Buschenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proceedings of the National Academy of Sciences USA. 1989;86(8):2804–2808
  49. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. Journal of Leukocyte Biology. 2003;73(1):3–29
  50. Halpern BN, Biozzi G, Stiffel C, Mouton D. Inhibition of tumour growth by administration of killed Corynebacterium parvum. Nature. 1966;212(64):853–854
  51. Key ME, Hanna MG. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. II. Influence of the local inflammatory response on immune reactivity. Journal of the National Cancer Institute. 1981;67(4):863–869
  52. Eilber FR, Townsend CM, Morton DL. Results of BCG adjuvant immunotherapy for melanoma of the head and neck. American Journal of Surgery. 1976;132(4):476–479
  53. Green AA, Pratt C, Webster RG, Smith K. Immunotherapy of osteosarcoma patients with virus-modified tumor cells. Annals of the New York Academy of Sciences. 1976;277(00):396–411
  54. Sinkovics JG. Immunotherapy with viral oncolysates for sarcoma. Journal of the American Medical Association. 1977;237(9):869
  55. Wallack MK, Steplewski Z, Koprowski H, Rosato E, George J, Hulihan B, et al. A new approach in specific, active immunotherapy. Cancer. 1977;39(2):560–564
  56. Berthier-Vergnes O, Portoukalian J, Leftheriotis E, Dore JF. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates. Cancer Research. 1994;54(9):2433–2439
  57. Jindal S, Young RA. Vaccinia virus infection induces a stress response that leads to association of Hsp70 with viral proteins. Journal of Virology. 1992;66(9):5357–5362
  58. Sedger L, Ruby J. Heat shock response to vaccinia virus infection. Journal of Virology. 1994;68(7):4685–4689
  59. Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y. Immunotherapy of tumor-bearing mice utilizing virus help. Cancer Immunology and Immunotherapy. 1988;27(3):223–227
  60. Hersey P, Coates AS, McCarthy WH, Thompson JF, Sillar RW, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. Journal of Clinical Oncology. 2002;20(20):4181–4190
  61. Wallack MK, Scoggin SD, Sivanandham M. Active specific immunotherapy with vaccinia melanoma oncolysate. Mt. Sinai Journal of Medicine. 1992;59(3):227–233
  62. Prabakaran I, Menon C, Xu S, Gomez-Yafal A, Czerniecki BJ, Fraker DL. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells. Annals of Surgical Oncology. 2002;9(4):411–418
  63. Wallack MK, Sivanandham M. Clinical trials with VMO for melanoma. Annals of the New York Academy of Sciences. 1993;690(178-89):
  64. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer. 1995;75(1):34–42
  65. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. Journal of Clinical Oncology. 2001;19(9):2370–2380
  66. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. Journal of Clinical Oncology. 1995;13(11):2776–2783
  67. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. Journal of Clinical Oncology. 2000;18(12):2444–2458
  68. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology. 1996;14(1):7–17
  69. Morton DL. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma. Developmental Biology (Basel). 2004;116(209–17):(discussion 229–36)
  70. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. Journal of the National Cancer Institute. 1998;90(24):1894–1900
  71. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology. 2005;23(10):2346–2357
  72. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Current Opinion in Immunology. 2005;17(2):195–201
  73. Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clinical Cancer Research. 2004;10(1 Pt 1):76–83
  74. Wallack MK, Sivanandham M, Ditaranto K, Shaw P, Balch CM, Urist MM, et al. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Annals of Surgery. 1997;226(2):198–206
  75. Banchereau J, Ueno H, Dhodapkar M, Connolly J, Finholt JP, Klechevsky E, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. Journal of Immunotherapy. 2005;28(5):505–516
  76. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proceedings of the National Academy of Sciences USA. 1995;92(17):8078–8082
  77. Palucka AK, Dhodapkar MV, Paczesny S, Ueno H, Fay J, Banchereau J. Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. Journal of Immunotherapy. 2005;28(2):158–168
  78. Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. International Journal of Oncology. 2002;21(4):685–694
  79. Abdel-Wahab Z, DeMatos P, Hester D, Dong XD, Seigler HF. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280–288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Cell Immunology. 1998;186(1):63–74
  80. Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clinical Cancer Research. 2002;8(4):1021–1032
  81. Coulon V, Ravaud A, Gaston R, Delaunay M, Pariente JL, Verdier D, et al. In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates. International Journal of Cancer. 2000;88(5):783–790
  82. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Research. 2001;61(6):2618–2624
  83. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proceedings of the National Academy of Sciences USA. 1998;95(16):9482–9487
  84. Neves AR, Ensina LF, Anselmo LB, Leite KR, Buzaid AC, Camara-Lopes LH, et al. Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunology and Immunotherapy. 2005;54(1):61–66
  85. Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine. 2005;23(17–18):2367–2373
  86. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood. 2002;99(5):1676–1682
  87. Okano F, Merad M, Furumoto K, Engleman EG. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity. Journal of Immunology. 2005;174(5):2645–2652
  88. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society of London B—Biological Sciences. 1957;147(927):258–267
  89. Bart RS, Porzio NR, Kopf AW, Vilcek JT, Cheng EH, Farcet Y. Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Research. 1980;40(3):614–619
  90. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. Journal of Clinical Oncology. 2001;19(5):1430–1436
  91. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clinical Cancer Research. 2004;10(5):1670–1677
  92. Kefford RF. Adjuvant therapy of cutaneous melanoma: the interferon debate. Annals of Oncology. 2003;14(3):358–365
  93. Lawson DH. Update on the systemic treatment of malignant melanoma. Seminars in Oncology. 2004;31(2 Suppl 4):33–37
  94. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193(4257):1007–1008
  95. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. Journal of Experimental Medicine. 1985;161(5):1169–1188
  96. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. Journal of Immunotherapy. 2001;24(4):363–373
  97. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. Journal of the American Medical Association. 1986;256(22):3117–3124
  98. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New England Journal of Medicine. 1985;313(23):1485–1492
  99. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Annals of Surgery. 1998;228(3):307–319
  100. Eklund JW, Kuzel TM. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Cancer Treatment and Research. 2005;126:263–287
  101. Kilbourn RG, Fonseca GA, Trissel LA, Griffith OW. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-l-arginine. Cancer Journal from Scientific American. 2000;6(Suppl 1):S21–S30
  102. Atkins MB. Interleukin-2 in metastatic melanoma: what is the current role?. Cancer Journal from Scientific American. 2000;6(Suppl 1):S8–S10
  103. Dillman RO, Church C, Barth NM, Oldham RK, Wiemann MC. Long-term survival after continuous infusion interleukin-2. Cancer Biotherapy and Radiopharmaceuticals. 1997;12(4):243–248
  104. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. Journal of Clinical Oncology. 2003;21(13):2564–2573
  105. Agarwala SS, Glaspy J, O’Day SJ, Mitchell M, Gutheil J, Whitman E, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. Journal of Clinical Oncology. 2002;20(1):125–133
  106. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. Journal of Clinical Oncology. 2002;20(8):2045–2052
  107. Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Journal of Clinical Oncology. 1997;15(7):2579–2588
  108. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. Journal of Clinical Oncology. 1999;17(3):968–975
  109. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. Journal of the National Cancer Institute. 1987;79(5):1067–1075
  110. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318–1321
  111. Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. Journal of Clinical Oncology. 1988;6(5):839–853
  112. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New England Journal of Medicine. 1988;319(25):1676–1680
  113. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Journal of the National Cancer Institute. 1994;86(15):1159–1166
  114. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. Journal of Immunotherapy. 2002;25(3):243–251
  115. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. Journal of Immunology. 2005;175(10):7046–7052
  116. Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Research. 2005;65(5):2001–2008
  117. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. Journal of Experimental Medicine. 1996;183(6):2533–2540
  118. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. Journal of Immunology. 1999;162(10):5813–5820
  119. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. Journal of Experimental Medicine. 1996;183(6):2541–2550
  120. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–547
  121. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences USA. 2003;100(14):8372–8377
  122. Sivanandham M, Kim EM, Wallack MK. Experimental melanoma vaccines. IDrugs. 2002;5(2):159–170
  123. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine. 1998;4(3):321–327
  124. Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003;98(1):144–154
  125. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Human Gene Therapy. 2003;14(8):709–714
  126. Berd D, Maguire HC, Schuchter LM, Hamilton R, Hauck WW, Sato T, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. Journal of Clinical Oncology. 1997;15(6):2359–2370
  127. Berd D, Sato T, Cohn H, Maguire HC, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. International Journal of Cancer. 2001;94(4):531–539
  128. Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. Journal of Clinical Oncolog. 2004;22(3):403–415
  129. Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer. 1992;69(5):1157–1164
  130. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clinical Cancer Research. 2001;7(7):1882–1887
  131. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Annals of Surgery. 1992;216(4):463–482
  132. Faries MB, Morton DL. Therapeutic vaccines for melanoma: current status. BioDrugs. 2005;19(4):247–260
  133. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau HY, Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Research. 1988;48(20):5883–5893
  134. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Seminars in Oncology. 1998;25(6):623–635
  135. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. Journal of Clinical Oncology. 2002;20(8):2067–2075
  136. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. Journal of Clinical Oncology. 2002;20(8):2058–2066
  137. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, et al. Active-specific immunotherapy for melanoma. Journal of Clinical Oncology. 1990;8(5):856–869
  138. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. Journal of Immunotherapy. 2004;27(5):354–367
  139. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Research. 2001;61(17):6451–6458
  140. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. Journal of Immunotherapy. 2001;24(1):66–78
  141. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. Journal of Experimental Medicine. 1999;190(11):1669–1678
  142. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine. 1998;4(3):328–332
  143. O’Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunology and Immunotherapy. 2003;52(6):387–395
  144. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Research. 2003;13(5):521–530
  145. Griffioen M, Borghi M, Schrier PI, Osanto S, Schadendorf D. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunology and Immunotherapy. 2004;53(8):715–722
  146. Hersey P, Menzies SW, Halliday GM, Nguyen T, Farrelly ML, DeSilva C, et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunology and Immunotherapy. 2004;53(2):125–134
  147. Vilella R, Benitez D, Mila J, Lozano M, Vilana R, Pomes J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunology and Immunotherapy. 2004;53(7):651–658
  148. Escobar A, Lopez M, Serrano A, Ramirez M, Perez C, Aguirre A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clinical Immunology. 2005;142(3):555–568
  149. Wallack MK, Meyer M, Bourgoin A, Dore JF, Leftheriotis E, Carcagne J, et al. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. Journal of Response Modifiers. 1983;2(6):586–596
  150. Wallack MK, Michaelides M. Serologic response to human melanoma lines from patients with melanoma undergoing treatment with vaccinia melanoma oncolysates. Surgery. 1984;96(4):791–800
  151. Wallack MK, McNally KR, Leftheriotis E, Seigler H, Balch C, Wanebo H, et al. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer. 1986;57(3):649–655
  152. Wallack MK, Bash JA, Leftheriotis E, Seigler H, Bland K, Wanebo H, et al. Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Archives of Surgery. 1987;122(12):1460–1463
  153. Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. Journal of Immunology. 1996;156(10):3882–3891
  154. Sivanandham M, Scoggin SD, Tanaka N, Wallack MK. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunology and Immunotherapy. 1994;38(4):259–264
  155. Tanaka N, Sivanandham M, Wallack MK. Immunotherapy of a vaccinia colon oncolysate prepared with interleukin-2 gene-encoded vaccinia virus and interferon-alpha increases the survival of mice bearing syngeneic colon adenocarcinoma. Journal of Immunotheraphy Emphasis Tumor Immunology. 1994;16(4):283–293

PII: S0960-7404(06)00020-X

doi: 10.1016/j.suronc.2006.05.003

Surgical Oncology
Volume 15, Issue 1 , Pages 13-24 , July 2006

Article Tools